Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria: * （1）Age ≥18 years old, no gender limit ; * （2）be diagnosed with AML (non-M3) according to WHO 2016 standards; * （3）No previous treatment; * （4）Ineligible for intensive chemotherapy based on the following definitions: ≥75 years of age or 18 to 74 years of age with at least one of the following comorbidities: Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3 A history of cardiac disease such as congestive heart failure Treatment is required, or ejection fraction ≤ 50%, or chronic stable angina, diffusing capacity of lung for carbon monoxide (DLCO) ≤ 65%, or forced expiratory volume in first second (FEV1) ≤ 65%, creatinine clearance ≥ 30 mL/min to \< 45 mL/min, moderate hepatic impairment, total bilirubin \> 1.5 to ≤ 3.0 × ULN, other comorbidities that are not suitable for intensive chemotherapy in the physician's judgment. * （5）Subjects must have an ECOG performance status score of: 0 to 2 for subjects aged ≥ 75 years or 0 to 3 for subjects aged ≥ 18 to 74 years. * （6）Other comorbidities that are not suitable for intensive chemotherapy in the doctor's judgment; * （7）Expected survival time ≥3 months; * （8）Have the ability to understand and be willing to sign the informed consent form for this study. Exclusion Criteria: * (1) Combined with other malignant tumors * (2) Have ever received treatment with chidamide and / or venetoclax or azacitidine; * (3) The risk is assessed as low risk according to the NCCN 2022 guidelines \[t(8;21)(q22;q22.1);RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16 )(p13.1;q22);CBFB-MYH11 \] ; * (4) The subject is known to have AML central nervous system (CNS) infiltration; * (5) Have undergone cardiac angioplasty or stent placement within 12 months before signing the informed consent form , or have a history of myocardial infarction, unstable angina, or other clinically significant heart disease; * (6 ) Active infections (including bacterial, fungal or viral infections) and organ bleeding that cannot be controlled clinically; * (7) Pregnant or lactating women; * (8) Participated in any other clinical research within 3 months before signing the informed consent form ; * (9 ) The researcher believes that it is not suitable to participate in this study;